Skip to main content


A phase 1/2 clinical trial in healthy adults and adults with Type 2 diabetes.

About COVALENT-111

What does it mean to be randomized, double-blind, placebo-controlled study?

It means that 5 out of 6 patients will receive the BMF-219, the study drug, and 1 out of 6 patients will receive placebo for each dose level. This allocation will be based on chance and neither the treating physician nor the patient will know their assignment during the treatment period.

Will it cost me anything?

Study medication and study-related care will be provided at no cost.

Phase II Patient eligibility 

18 – 65 years
Female & Male
Type 2 Diabetes
  • Be 18 to 60 years of age
  • All sexes included
  • Diagnosed with Type 2 diabetes within the last 15 years

And also:

  • HbA1c ≥ 7.0% and ≤ 10%
  • BMI ≥ 25 and ≤ 40 kg/m2

The science behind COVALENT-111

What is BMF-219?

BMF-219 is an investigational, orally bioavailable small molecule, which covalently binds to the scaffold protein menin, an important transcriptional regulator known to play a direct role in regulating beta cell growth.

Contact us

Our clinical trials team will contact you shortly after your form submission.